Author

Siddalingaiah Ningaiah

Institution: Biological E (India)

Observed institution: Biological E (India)

ORCID: 0009-0006-6116-4959

Observed ORCID: 0009-0006-6116-4959

OpenAlex ID: A5118577359

Immunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial

2026 · Subhash Thuluva, Ramesh V. Matur, et al. · The Lancet Regional Health - Southeast Asia · 4

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial

2025 · Subhash Thuluva, Vikram Paradkar, et al. · The Lancet Regional Health - Southeast Asia · 4

Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · BMC Infectious Diseases · 1

Association Between Pre-Existing Anti-Diphtheria Toxoid IgG and Immune Responses to a CRM197-Conjugated 14-Valent Pneumococcal Conjugate Vaccine in Infants: A Post Hoc Analysis of a Multicenter Phase III Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Vaccines

Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Vaccines

Immunogenicity and Safety of Biological E’s Monovalent rDNA Hepatitis B Vaccine (BEVAC®) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Viruses

Corrigendum to ‘Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study’ [IJID Regions, volume 17 (2025) 100786]

2026 · Subhash Thuluva, Vikram Paradkar, et al. · IJID Regions

Immunogenicity and Safety of Biological E’s 14-valent Pneumococcal Conjugate Vaccine Pneubevax 14® in a 2+1 Infant Schedule: Multicenter, Randomized, Active-controlled, Single-blind Phase Iii Trial

2026 · Thuluva, Subhash, Matur, Ramesh, et al.

Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply

2025 · Subhash Thuluva, Vikram Paradkar, et al. · The Lancet Regional Health - Southeast Asia

Works count: 9

Citation count: 9

H-index: 2

I10-index: